Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Details
Category: Globe NewsWire News Distribution Service

CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660.…


Posted: 2025-01-10 11:02:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | mersana | therapeutics | announces


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) - Newscast

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts

Fri, 24 Jan 2025 21:21:00 GMT Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...

Mersana Therapeutics, Inc. (MRSN)

Wed, 22 Jan 2025 16:00:00 GMT On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated, with no ...

Mersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)

Mon, 13 Jan 2025 00:04:00 GMT Mersana Therapeutics, Inc. recently disclosed encouraging updates in a Form 8-K report filed with the Securities and Exchange Commission. The company unveiled positive initial clinical data from the ...

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Fri, 10 Jan 2025 13:04:00 GMT Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ ... Forward-Looking Statements This press release contains “forward-looking” statements and information ...

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted To Emiltatug Ledadotin (XMT-1660)

Thu, 09 Jan 2025 22:16:00 GMT (MENAFN- GlobeNewsWire - Nasdaq) conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics ...


Blow Us A Whistle